Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gene Contribution of Streptococcus dysgalactiae Subspecies equisimilis, an Emerging Pathogen, to Experimental Primate Necrotizing Myositis.

The American journal of pathology·2026

Same author

Cell cycle pathway alterations predict outcomes post-liver transplantation for hepatocellular carcinoma.

Frontiers in transplantation·2026

Same author

Genomic and patient epidemiology of <i>Streptococcus dysgalactiae</i> subspecies <i>equisimilis</i> in Houston, Texas.

Microbiology spectrum·2026

Same author

Tricuspid valve endocarditis in a horse owner, caused by <i>Streptococcus equi</i> subsp. <i>zooepidemicus</i>.

ASM case reports·2025

Same author

Intrahost Genomic Variation of Haemophilus influenzae Isolates from Asymptomatic Nasopharyngeal Carriers Involves Genes Encoding Proteins with Diverse Inferred Functions.

The American journal of pathology·2025

Same author

Analysis of <i>Streptococcus dysgalactiae</i> subspecies <i>equisimilis</i> gene transcripts during experimental primate necrotizing myositis.

mBio·2025

Search research articles

Related Experiment Video

Updated: May 8, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

Published on: October 26, 2017

Lung cancer biomarkers: present status and future developments.

Philip T Cagle¹, Timothy Craig Allen, Randall J Olsen

¹Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, Texas 77030, USA. pcagle@tmhs.org

Archives of Pathology & Laboratory Medicine

|September 3, 2013

Summary

The College of American Pathologists guideline offers a framework for biomarker testing in lung cancer patients receiving EGFR and ALK tyrosine kinase inhibitors. This advances precision medicine by defining the pathologist's role in targeted therapy selection.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Experiment Videos

Last Updated: May 8, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

Published on: October 26, 2017

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Area of Science:

Oncology
Molecular Pathology
Genomics

Background:

Biomarker testing is crucial for selecting lung cancer patients for targeted therapies.
First-generation EGFR and ALK tyrosine kinase inhibitors have transformed lung cancer treatment.
The role of pathologists in lung cancer management has significantly evolved with molecular diagnostics.

Purpose of the Study:

To present the "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors."
To provide a standardized approach for biomarker testing in lung cancer.
To address the evolving landscape of precision medicine in lung cancer.

Main Methods:

The guideline was developed by the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
It focuses on molecular testing strategies for EGFR and ALK mutations.
The guideline addresses the selection of patients for specific tyrosine kinase inhibitors.

Main Results:

A comprehensive guideline for biomarker testing for first-generation EGFR and ALK inhibitors is now available.
The guideline clarifies the essential role of pathologists in precision oncology.
It establishes a foundation for current and future molecular testing in lung cancer.

Conclusions:

The guideline represents a significant step in standardizing molecular testing for lung cancer treatment.
Ongoing advancements in biomarker tests, drugs, and technologies will further refine precision medicine.
Improving the cost-benefit ratio of biomarker testing is essential for broader clinical implementation.